
Opinion|Videos|April 11, 2025
Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis
Panelists discuss how when prescribing an IL-17 inhibitor, key safety considerations include infection risk (particularly tuberculosis and fungal infections), inflammatory bowel disease exacerbation, allergic reactions, neutropenia, immunogenicity, vaccination timing, pregnancy/breastfeeding status, malignancy history, and monitoring requirements for adverse events.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What safety data do you take into consideration when prescribing an IL-17 inhibitor?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie to Acquire Apogee Therapeutics, Expanding AD Pipeline With Zumilokibart
2
Ycanth Phase 3 Trial Dosing Begins for Common Warts in US, Japan
3
David Rosmarin, MD, on CHE Heterogeneity and Unmet Needs in AD and Vitiligo
4
Peter Lio, MD, Discusses Atopic Dermatitis Treatment Strategy and Microbiome-Targeted Therapies
5
















